98 Cases Of Clinical Observation Of Myelosuppression After Chemother-Apy For Ovarian Malignantt Umour

Objective:By studying the characteristics of severe myelosuppression after chemotherapy in ovarian malignant tumors and related influencing factors,in order to provide a clinical reference for the prevention of severe myelosuppression after chemotherapy in clinical ovarian malignant tumors.Method:We searched our hospital's electronic medical record system for our department.From January 2016 to December 201818,we had 310 cases of bone marrow suppression after chemotherapy for ovarian malignant tumors.98 cases/times were included in the study.Patients were divided into mild and severe myelosuppression groups.The patients' age,chemotherapy regimen,chemotherapy regimen and other general conditions were retrospectively analyzed,and the characteristics of severe myelosuppression and related influencing factors were analyzed.Result:Among the 98 patients with ovarian malignant tumors who received myelosuppression after chemotherapy,single factor analysis showed that different age groups,different chemotherapy courses,and pre-chemotherapy hemoglobin had a significant effect on severe(III-IV degree)myelosuppression.The probability of severe(III-IV)myelosuppression after chemotherapy with paclitaxel plus platinumbased chemotherapy regimen was 44.9%,and the probability of severe bone marrow(III-IV degree)inhibition after non-TP regimen chemotherapy was 30.0%,the difference was meaningless(P> 0.05).Platinum includes 53 cases of nataplatin/time,and 25 cases of carboplatin.In severe myelosuppression,the probability of severe(III-IV degree)myelosuppression in the nedaplatin group was 56.7%;the probability of severe(III-IV degree)myelosuppression in the carboplatin group was 20%,and the difference was statistically significant(P < 0.05).Multivariate analysis of severe(IIIIV degree)myelosuppression showed that 3-6 chemotherapy courses,50-60 years old,and pre-chemotherapy hemoglobin reduction were risk factors for severe(III-IVdegree)myelosuppression.In conclusion:1?50-60 years old,3-6 chemotherapy courses are high-risk groups of severe myelosuppression after chemotherapy for ovarian malignant tumors.2?HB-lowering before chemotherapy may be one of the risk factors for severe myelosuppression after chemotherapy for ovarian malignant tumors.3 ? Nidaplatin in platinum drugs has a high probability of severe myelosuppression after chemotherapy for ovarian malignancies.